Intercell expands late-stage pipeline with $189 million Iomai acquisition

| 2 min read
Register for free to listen to this article
Listen with Speechify
0:00
2:00
VIENNA, Austria—Intercell AG  and Iomai Corp. announced yesterday that thecompanies entered into a definitive agreement pursuant to which Intercell willacquire Iomai for $6.60 per share representing a fully diluted equity value ofapproximately $189 million. Intercell will gain full rights to Iomai's latestage Travelers' Diarrhea vaccine which is based on Iomai's proprietaryneedle-free patch delivery vaccine technology and has shown positive interimPhase II efficacy data. The Travelers' Diarrhea vaccine is expected to enterpivotal Phase III trials in the first half of 2009.

 
"We have built a dynamic and scientifically drivenorganization," says Stanley C. Erck, president and CEO of Iomai. "Thisstrategic combination with Intercell will create a stronger, more diversifiedvaccine company, will accelerate the development of Iomai's vaccine programsand fully leverage our innovative TCI technology."

 
If approved, the medical use of Iomai's Travelers' Diarrheavaccine will be highly complementary with Intercell's Japanese Encephalitisvaccine for which a Biologics License Application was successfully submitted tothe FDA in December 2007, and for which Intercell expects market approvals inthe US, Europe and Australia later this year. Together, according to thecompanies, both vaccines will a Traveler's Vaccine franchise which will targeta combined market opportunity of over $1 billion in sales per year.

 
"This transaction further expands our leadership in vaccineinnovation, greatly enhances Intercell's R&D technology base and furtherstrengthens our late stage vaccine portfolio," says Gerd Zettlmeissl, CEO ofIntercell. "Building on our proven experience in industrialization and inmoving novel products to the market, Intercell is fully committed to becomingthe leading pure play vaccine company globally."

 
The vaccine for traveler's diarrhea has a large potentialmarket, as each year approximately 55 million international travelers willvisit countries where bacteria that cause travelers' diarrhea are endemic,particularly Africa, Asia and Latin America. The CDC estimates that 20 to 50 percent of internationaltravelers contract diarrhea. Of greater concern is the effects can progressbeyond acute symptoms. Between 10 and 30 percent of those who developtravelers' diarrhea will develop the chronic symptoms of irritable bowelsyndrome.

 
Intercell will also gain full rights to two additionalclinical and three preclinical programs under development, the most advancedbeing an immunostimulant vaccine patch in Phase II for pandemic influenza. Thispatch is designed to enhance the immune response compared to injected pandemicinfluenza vaccines. If successful, it would have the effect of expandinglimited vaccine supplies by allowing public health officials to use fewer orlower doses of the vaccine. 

 

About the Author

Related Topics

Loading Next Article...
Loading Next Article...
Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

Close-up illustration of clustered, irregularly shaped 3D cell structures resembling organoids, displayed in a blue-toned background.
Machine learning-powered image analysis makes it possible to automatically and reliably quantify complex 3D cell structures.
Illustration of a glowing human brain with interconnected neural networks and bright data points, set against a dark, digital background.
Take a closer look at modern techniques that reveal when, where, and how neurons communicate in real time.
Gloved hand holding a petri dish containing red liquid culture medium against a light blue background.
As global regulations shift toward animal-free testing, how can researchers develop more biologically relevant in vitro models to advance drug discovery?
Drug Discovery News June 2025 Issue
Latest IssueVolume 21 • Issue 2 • June 2025

June 2025

June 2025 Issue

Explore this issue